产品说明书
Teriflunomide
 |
同义名 : | A77 1726;Flucyamide;SU 20;HMR-1726 |
| CAS号 : | 163451-81-8 | |
| 货号 : | A122692 | |
| 分子式 : | C12H9F3N2O2 | |
| 纯度 : | 99%+ | |
| 分子量 : | 270.207 | |
| MDL号 : | MFCD00910058 | |
| 存储条件： |
粉末 Sealed in dry,Store in freezer, under -20°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 35 mg/mL(129.53 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 靶点 |
|
||
| 描述 | Teriflunomide primarily inhibits dihydroorotate dehydrogenase (DHODH), crucial in pyrimidines' de novo synthesis, thereby reducing high-avidity proliferating T and B lymphocytes' activity and potentially moderating autoantigen-induced inflammation in MS, making it more cytostatic than cytotoxic towards leukocytes[1]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT02509052 | Recurrent Plasma Cell Myeloma ... 展开 >> Refractory Plasma Cell Myeloma 收起 << | Phase 1 Phase 2 | Active, not recruiting | June 2019 | United States, California ... 展开 >> City of Hope Medical Center Duarte, California, United States, 91010 收起 << |
| NCT02559765 | - | Completed | - | United Kingdom ... 展开 >> The University of Glasgow Glasgow, United Kingdom, G12 8LL 收起 << | |
| NCT03709446 | Breast Neoplasms ... 展开 >> Breast Diseases Metastatic Triple Negative Breast Cancer 收起 << | Phase 1 Phase 2 | Not yet recruiting | October 20, 2021 | United States, New York ... 展开 >> Icahn School of Medicine at Mount Sinai Not yet recruiting New York, New York, United States, 10029 Contact: Charles Shapiro, MD 212-241-3131 charles.shapiro@mssm.edu Contact: Joni Gomes, BSN 212-824-7076 joni.gomes@mssm.edu 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
3.70mL 0.74mL 0.37mL |
18.50mL 3.70mL 1.85mL |
37.01mL 7.40mL 3.70mL |
| 参考文献 |
|---|